GSK, Sanofi, and CSL Secure $72 Million BARDA Funding to Enhance Bird Flu Vaccine Supply

BARDA Funding:
The Biomedical Advanced Research and Development Authority (BARDA) has awarded $72 million to GSK, Sanofi, and CSL to boost the supply of bird flu vaccines in the United States.

Companies Involved:
The funding recipients include GlaxoSmithKline (GSK), Sanofi, and CSL Seqirus, all of which are major pharmaceutical companies with expertise in vaccine development and production.

Public Health Impact:
The funding aims to enhance the country's preparedness against potential bird flu outbreaks by increasing the availability of vaccines.

Recent Developments:
This funding announcement comes at a time when Sanofi has also made headlines for selling the global rights to its autoimmune drug Enjaymo to Recordati for $825 million.